Suzetrigine

Suzetrigine
Clinical data
Other names	VX-548
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[[(2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide;
CAS Number	2649467-58-1;
PubChem CID	156445116;
UNII	LOG73M21H5;
Chemical and physical data
Formula	C21H20F5N3O4
Molar mass	473.400 g·mol−1

Suzetrigine (VX-548) is a non-opioid, small-molecule analgesic that works as a selective inhibitor of Nav1.8.^[1] It is being developed by Vertex Pharmaceuticals and is currently in Phase II trials.^[2]^[3]

References

↑ Jones, Jim; Correll, Darin J.; Lechner, Sandra M.; Jazic, Ina; Miao, Xiaopeng; Shaw, David; Simard, Christopher; Osteen, Jeremiah D.; Hare, Brian; Beaton, Alina; Bertoch, Todd; Buvanendran, Asokumar; Habib, Ashraf S.; Pizzi, Lois J.; Pollak, Richard A.; Weiner, Scott G.; Bozic, Carmen; Negulescu, Paul; White, Paul F. (3 August 2023). "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain". The New England Journal of Medicine. 389 (5): 393–405. doi:10.1056/NEJMoa2209870. ISSN 1533-4406. PMID 37530822. S2CID 260377748.
↑ "Non-opioid pain pill shows promise in clinical trials: Vertex Pharmaceuticals plans larger trials that could support approval". Retrieved 4 November 2023.
↑ "VX-548 by Vertex Pharmaceuticals for Neuropathic Pain (Neuralgia): Likelihood of Approval". Pharmaceutical Technology. 4 March 2023. Retrieved 4 November 2023.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Jones, Jim; Correll, Darin J.; Lechner, Sandra M.; Jazic, Ina; Miao, Xiaopeng; Shaw, David; Simard, Christopher; Osteen, Jeremiah D.; Hare, Brian; Beaton, Alina; Bertoch, Todd; Buvanendran, Asokumar; Habib, Ashraf S.; Pizzi, Lois J.; Pollak, Richard A.; Weiner, Scott G.; Bozic, Carmen; Negulescu, Paul; White, Paul F. (3 August 2023). "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain". The New England Journal of Medicine. 389 (5): 393–405. doi:10.1056/NEJMoa2209870. ISSN 1533-4406. PMID 37530822. S2CID 260377748.

[2] "Non-opioid pain pill shows promise in clinical trials: Vertex Pharmaceuticals plans larger trials that could support approval". Retrieved 4 November 2023.

[3] "VX-548 by Vertex Pharmaceuticals for Neuropathic Pain (Neuralgia): Likelihood of Approval". Pharmaceutical Technology. 4 March 2023. Retrieved 4 November 2023.

[1]

[2]

[3]

See also

References